Akademik Veri Yönetim Sistemi
ANNALS OF ONCOLOGY, cilt.36, sa.2025, ss.1565-1566, 2025 (SCI-Expanded, Scopus)
Background: In RAIR-DTC, treatment with tyrosine kinase inhibitors (TKIs) such as sorafenib has shown promising results. Despite such advances in treatment, prognostic factors affecting survival are still poorly understood and treatment management is challenging due to the heterogeneity of the disease and the pathways through which treatment resistance can occur. We investigated the efficacy and side effect profile of sorafenib treatment in this patient group. We investigated the effects of cumulative RAI dose, histological subtype, biochemical parameters, metastases, and demographic characteristics on PFS and OS in RAIR-DTC. Methods:Our retrospective multicenter study included 160 patients who received sorafenib treatment due to RAIR-DTC between 2000 and 2023. SPSS 15.0 program was used for statistical analysis. The rates in the groups were compared with the Chi Square Test. Dose reduction effective on PFS and OS, metastasis status, metastasectomy, histological subtype, demographic data were examined with Cox Regression Analysis. Statistical alpha significance level was accepted as p<0.05. Results:137 patients (90.1%) received sorafenib in the first line and 23 patients in the second-third line and PFS was 20 months (15.9-24.1). CR was observed in 3 patients (2.1%), PR in 58 patients (40.8), SD in 55 patients (38.7) and progression in 26 patients (18.3%). In terms of PFS, age, liver metastasis and dose reduction had a p˂0.250 risk effect. In the model created with the Bacward Method, a statistically significant 1.04-fold increase in age and a 3.217-fold increase in Sorafenib dose reduction were found. The most common side effect was skin toxicity (80 patients, 50%). Only 1 patient discontinued treatment due to treatment intolerance. Conclusions:Our study is one of the few studies that demonstrate the efficacy of sorafenib in this rare patient group, and a PFS of up to 2 times greater than that of the phase 3 study was observed in patients. And it contributes to revealing the factors affecting PFS. Our goal is to further expand our patient population and obtain a detailed study that will examine the relationship between molecularly targeted therapies and median survival times.